Invasive Fungal Disease Associated With Targeted Agents for Acute Myeloid Leukaemia: A Systematic Review
Open Access
Abstract
Objective: To examine the incidence of invasive fungal disease (IFD) in patients receiving targeted agents for acute myeloid leukaemia (AML).Methods: Literature for this systematic review was identified through a PubMed search in April 2024, using AML, IFD and targeted therapy terms. The following filters were applied: published in the last 10 years and published in English.Results: The PubMed search yielded 54 results, of which 16 were deemed relevant for inclusion. Four additional references were identified through manual searches. The majority of publications focused on the incidence of IFD during treatment with targeted agents; the remainder focused on the efficacy of targeted treatments and reported IFD as an adverse event. Most publications were retrospective analyses. Prophylaxis use and agents differed across studies. In several studies, IFD incidence was above the 8% threshold identified for anti‐mould prophylaxis. Aspergillus was the most commonly reported pathogen, and most IFD cases occurred in the lungs.Conclusions: IFD is relatively common among patients with AML receiving targeted therapies, despite the use of prophylaxis. Prospective studies with detailed IFD reporting, together with large epidemiological studies, are required to better understand the risk factors for, and incidence and nature of IFD in this patient population.Keywords
This publication has 51 references indexed in Scilit:
- European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in LeukaemiaJournal of Antimicrobial Chemotherapy, 2018
- ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors)Clinical Microbiology and Infection, 2018
- Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b studyThe Lancet Oncology, 2018
- Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 studyThe Lancet Oncology, 2017
- Delivering on Antimicrobial Resistance Agenda Not Possible without Improving Fungal Diagnostic CapabilitiesEmerging Infectious Diseases, 2017
- The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic LeukemiaCurrent Hematologic Malignancy Reports, 2017
- Defining invasive fungal infection risk in hematological malignancies: a new tool for clinical practiceMediterranean Journal of Hematology and Infectious Diseases, 2016
- ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipientsJournal of Antimicrobial Chemotherapy, 2016
- A comprehensive diagnostic approach using galactomannan, targeted β‐d‐glucan, baseline computerized tomography and biopsy yields a significant burden of invasive fungal disease in at risk haematology patientsBritish Journal of Haematology, 2014
- Diagnostic methods for invasive fungal diseases in patients with hematologic malignanciesExpert Review of Hematology, 2012